Rapamycin Exerts Antifungal Activity In Vitro and In Vivo against Mucor circinelloides via FKBP12-Dependent Inhibition of Tor

Author:

Bastidas Robert J.1,Shertz Cecelia A.1,Lee Soo Chan1,Heitman Joseph123,Cardenas Maria E.1

Affiliation:

1. Departments of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA

2. Medicine, Duke University Medical Center, Durham, North Carolina, USA

3. Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA

Abstract

ABSTRACT The zygomycete Mucor circinelloides is an opportunistic fungal pathogen that commonly infects patients with malignancies, diabetes mellitus, and solid organ transplants. Despite the widespread use of antifungal therapy in the management of zygomycosis, the incidence of infections continues to rise among immunocompromised individuals. In this study, we established that the target and mechanism of antifungal action of the immunosuppressant rapamycin in M. circinelloides are mediated via conserved complexes with FKBP12 and a Tor homolog. We found that spontaneous mutations that disrupted conserved residues in FKBP12 conferred rapamycin and FK506 resistance. Disruption of the FKBP12-encoding gene, fkbA , also conferred rapamycin and FK506 resistance. Expression of M. circinelloides FKBP12 ( Mc FKBP12) complemented a Saccharomyces cerevisiae mutant strain lacking FKBP12 to restore rapamycin sensitivity. Expression of the Mc Tor FKBP12-rapamycin binding (FRB) domain conferred rapamycin resistance in S. cerevisiae , and Mc FKBP12 interacted in a rapamycin-dependent fashion with the Mc Tor FRB domain in a yeast two-hybrid assay, validating Mc FKBP12 and Mc Tor as conserved targets of rapamycin. We showed that in vitro , rapamycin exhibited potent growth inhibitory activity against M. circinelloides . In a Galleria mellonella model of systemic mucormycosis, rapamycin improved survival by 50%, suggesting that rapamycin and nonimmunosuppressive analogs have the potential to be developed as novel antifungal therapies for treatment of patients with mucormycosis.

Publisher

American Society for Microbiology

Subject

Molecular Biology,General Medicine,Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3